anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This Randomized controlled intervention study recruited patients diagnosed with ST-segment elevation myocardial infarction (STEMI) who were scheduled to undergo emergency percutaneous coronary intervention (PCI) . A total of 240 patients were selected for both the Henagliflozin group and control group. In the emergency room, clinical data would be collected, along with peripheral venous blood samples for laboratory examination. This examination should include blood routine analysis, myocardial enzyme, blood glucose levels, liver and kidney function, and brain natriuretic peptide precursor (NT proBNP) measurement. After primary PCI, Henggliflozin was administered, followed by daily oral administration of one tablet until 6 months post-acute myocardial infarction. Prior to procedure, dynamic changes in myocardial enzymes and electrocardiogram were monitored, with subsequent monitoring at 6 hours, 24 hours, and 48 hours after myocardial infarction. Perioperative complications were documented, followed by cardiac ultrasound assessments of myocardial wall motion and cardiac structure at seven days post primary PCI and six months post procedure. Major cardiovascular events, including non-fatal myocardial infarction, all-cause death, revascularization due to angina, and hospitalization for acute heart failure, were observed through follow-up at 1 month, 2 months, 3 months, and 6 months after PCI. This study aims to assess the impact of postoperative Henggelizin intervention on the reduction of myocardial infarction size and improvement of left ventricular remodeling in patients with ST-segment elevation myocardial infarction (STEMI).
Doxorubicin is one of the cornerstone therapies in adjuvant chemotherapy in early stage breast cancer. Cumulative doses of 240mg/m2 (4 cycles of doxorubicin/cyclophosphamide) and 300mg/m2 (6 cycles of doxorubicin/cyclophosphamide) are typically administered in the adjuvant setting, which is associated with \<1% chance of severe cardiotoxicity, and are thus considered 'safe dose ranges'. However, Blanco et al recently reported childhood cancer survivors with the CBR3 (a metabolizing enzyme of doxorubicin) V244M homozygous G genotypes to be at increased risk of cardiomyopathy following exposure to anthracyclines doses as low as 101-150mg/m2, suggesting that there is no safe dose threshold for individuals with certain genotypes. We have previously studied several genes in the doxorubicin pharmacology pathway, including CBR1, CBR3, and AKR1C3, and found correlation between functional variants in CBR3 and AKR1C3 with doxorubicin-induced myelosuppression. The CBR3 G allele is present in about 50-60% of the Singapore population, and we postulate that these common variants may similarly modify the risk of anthracyclines-induced cardiomyopathy in adult breast cancer patients. Post-treatment echocardiography is not routinely performed in patients who complete adjuvant anthracyclines-containing chemotherapy. We believe that some of these high-risk individuals may have subclinical reduced left ventricular ejection fraction that may in the future increase the risk of congestive cardiac failure in the presence of other risk factors (eg hypertension, anemia, serious infection, etc). Identifying these individuals could therefore be important as early treatment with ACE inhibitors may improve cardiac function. Confirming the correlation between genetic variants including the CBR3 V244M can also help to develop a predictive algorithm in the future to identify patients in whom anthracyclines should be avoided.
The invention discloses a Radix pueraiae fermentation protoplasm cosmetic product and a preparation method and application thereof. The preparation method includes following steps: using Radix pueraiae as a substrate and brewer's yeast as a strain for fermentation. Radix pueraiae fermentation protoplasm prepared by the method also belongs to the protection range of the invention.an active ingredient of the cosmetic product is the Radix pueraiae fermentation protoplasm. Functions of the cosmetic product includes (a) and/or (b) and/or (c) and/or (d), (a) refers to resisting oxidation, (b) refers to removing DPPH free radicals, (c) refers to promoting collagen synthesis, and (d) refers to resisting aging. Fermentation engineering technology is utilized to extract active substance from Radix pueraiae, so that operation is simple; no foreign substance is added, so that the Radix pueraiae fermentation protoplasm prepared by the method is safe and harmless to skin. The cosmetic product is rich in substances like polysaccharide and flavone which are synergistic with fermentation product ingredients in fermentation filtrate, so that resistance to oxidation and aging can be improved remarkably.
Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia.

1\. Supraventricular arrhythmias  
Intravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff‑Parkinson‑White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. 

2\. Ventricular tachycardias  
With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone (see DOSAGE AND ADMINISTRATION). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias.  
Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well‑being of the patient and do not respond to conventional measures. 

3\. Tachyarrhythmias of digitalis intoxication  
Intravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur (see OVERDOSAGE). 

4\. Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia  
Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure (see WARNINGS).
PURPOSE:To efficiently generate dialysis progress data. and also, to make it useful to an appropriate diagnosis by storing and managing diagnostic data, etc., of a dialyzing patient, and designating an examination, a doctor's opinion, a prescription, the condition of a disease, a case history, etc., of the dialyzing patient in an arbitrary period, based on its diagnostic data. CONSTITUTION:Dialysis recording card 30 having a format which can be read by an OCR device 13 is issued. Dialyzing patient information of a dialyzing patient being in the course of dialysis is recorded in each area of the card 30. Optical read to the card 30 is executed by the device 13, and based on the read information, an in-dialysis time transition data file is generated. Its information is read out, and displayed on a screen. Also, the contents of the information displayed on the screen is confirmed and corrected. Based on the information of its file, a dialysis recording progress table is generated. This dialysis recording progress table is displayed on the screen and printed.
The present invention concerns ergostadientriols which may be recovered from either the fungus R. oligosporus or the fungus R. oryzae as well as from soybeans which have been fermented with either of these fungi. Alternatively, the sterols may be chemically synthesized. The sterols of this invention are antioxidants which may be used in antioxidant compositions alone or preferably with one or more isoflavone. Of particular significance is the discovery that the ergostadientriols of this invention are useful in lowering serum cholesterol levels. Accordingly, this invention in a particularly preferred embodiment discloses pharmaceutical compositions containing one or more ergostadientriol. Finally, therapeutic methods which utilize pharmaceutical compositions in accordance with this invention are disclosed.
In North America, surplus dairy calves are sold soon after birth and often marketed through a third party (e.g., live auction, livestock dealer) before entering veal or dairy beef production. Previous work has demonstrated that a percentage of calves have failed transfer of passive immunity (FTPI) and clinical signs of disease on arrival at calf-raising facilities, but little is known regarding calf condition during marketing. The objectives of this cross-sectional study were to (1) estimate the prevalence of FTPI and poor health outcomes in surplus calves on arrival at livestock dealers, and (2) investigate the association between calf-level variables (body weight, sex, source) and health outcomes. Two livestock dealers in Ohio were visited 2 to 3 times per week, with approximately 28 calves enrolled in the study per visit for a total of 1,119 calves. One blood sample per calf was obtained to evaluate FTPI by measuring serum total protein concentrations (using a cutoff <5.1 g/dL). Calves were clinically evaluated for signs of arthritis, broken ribs or tail, dehydration, depression, diarrhea, fever, navel inflammation, and respiratory disease by 2 observers; health outcomes were dichotomized using clinically relevant cut points. Descriptive statistics were used to estimate the prevalence of calves with poor health outcomes. Multivariable logistic regression models were built to investigate the effect of body weight, sex, and source on health outcomes. Nineteen percent (206/1,091) of calves had FTPI.
The recent rediscovery of functional brown adipose tissue (BAT) in healthy adults has opened up the exciting possibility of manipulating BAT for obesity management, and it is imperative to develop BAT imaging modalities that are non-invasive and safe for repeated use. Given that heat is a specific end-product of uncoupling protein-1 (UCP-1)-mediated BAT, this study examines whether surface body temperature assessed using infrared (IR) thermography can be a non-invasive measure to accurately and precisely predict brown adipose tissue (BAT) activation upon cold stimulation, which involves verifying an semi-automated method for characterizing thermal images. In addition, this study also aims to validate the use of a whole-body calorimeter to pick up changes in energy expenditure upon cold-induced thermogenesis. Lean, healthy male volunteers will be recruited. Thermal imaging of cervical-supraclavicular BAT will be done using an IR camera to assess changes in BAT activation. Blood samples will also be drawn at regular intervals to track changes in serum metabolites upon BAT activation. All in all, this study hopes to provide more supporting evidence that IR thermography is a viable imaging modality that is non-invasive, safe and reproducible of studying BAT activity.
Randomised hypoxemia: i. without gas mask; ii. with gas mask; and iii. correction with FreeO2 and gas mask.
BACKGROUND: Being exposed to crises during pregnancy can affect maternal health through stress exposure, which can in return impact neonatal health. We investigated temporal trends in neonatal outcomes in Switzerland between 2007 and 2022 and their variations depending on exposure to the economic crisis of 2008, the flu pandemic of 2009, heatwaves (2015 and 2018) and the COVID-19 pandemic.
METHODS: Using individual cross-sectional data encompassing all births occurring in Switzerland at the monthly level (2007-2022), we analysed changes in birth weight and in the rates of preterm birth (PTB) and stillbirth through time with generalized additive models. We assessed whether the intensity or length of crisis exposure was associated with variations in these outcomes. Furthermore, we explored effects of exposure depending on trimesters of pregnancy.
RESULTS: Over 1.2 million singleton births were included in our analyses. While birth weight and the rate of stillbirth have remained stable since 2007, the rate of PTB has declined by one percentage point. Exposure to the crises led to different results, but effect sizes were overall small. Exposure to COVID-19, irrespective of the pregnancy trimester, was associated with a higher birth weight (+12 grams [95% confidence interval (CI) 5.5 to 17.9 grams]). Being exposed to COVID-19 during the last trimester was associated with an increased risk of stillbirth (odds ratio 1.24 [95%CI 1.02 to 1.50]). Exposure to the 2008 economic crisis during pregnancy was not associated with any changes in neonatal health outcomes, while heatwave effect was difficult to interpret.
CONCLUSION: Overall, maternal and neonatal health demonstrated resilience to the economic crisis and to the COVID-19 pandemic in a high-income country like Switzerland. However, the effect of exposure to the COVID-19 pandemic is dual, and the negative impact of maternal infection on pregnancy is well-documented. Stress exposure and economic constraint may also have had adverse effects among the most vulnerable subgroups of Switzerland. To investigate better the impact of heatwave exposure on neonatal health, weekly or daily-level data is needed, instead of monthly-level data.
An Ji Ruige triazole derivative and an anti-breast cancer application thereof. The invention belongs to the technical field of medicines, and particularly relates to synthesis of an advanced glycosylation end product receptor inhibitor and application thereof in the aspect of resisting breast cancer. The invention carries out framework transition on an alpha Ji Ruige structure, replaces the triazole of the original structure with 1,2,4-triazole, and then carries out structure derivation. The results of in vitro pharmacological activity experiments show that part of the derivatives have better growth inhibition effect on human triple negative breast cancer cell line SUM149, IC  50  Values from μ M to nM, with the best active compound being 0.220. + -. 0.034 μ M; the remaining compounds had lower cytotoxic activity and the inhibition at the maximum tested concentration (10. Mu.M) was < 50%.
BACKGROUND: The objective of this study is to compare and assess the efficacy and safety of low-molecular-weight heparin calcium (LMWH-Ca), followed by either warfarin or rivaroxaban, as treatment options for portal vein thrombosis (PVT) in patients with cirrhosis.
METHODS: In this pilot study, cirrhotic (with liver function score of Child-Pugh A) patients diagnosed with PVT who were not on anticoagulant therapy received 2 weeks of subcutaneous injections of LMWH-Ca. They were then randomized to either warfarin (a full course of oral warfarin for 6 months) or rivaroxaban (a full course of oral rivaroxaban for 2 months), with 30 cases in each group. After a treatment period of up to 6 months, a comparative analysis was performed to assess the efficacy and safety of both groups. Volumetric changes in PVT were monitored dynamically using enhanced computed tomography scans before treatment at week 2 and month 6.
RESULTS: There were no statistically significant differences in the clinical characteristics of the patients between the two groups. Rivaroxaban treatment reduced PVT median volume from 1.83 cm3 at week 2 to 0.0 cm3 at month 6 and prevented the worsening of PVT after 6 months of treatment with LMWH-Ca (P < 0.001). On the other hand, warfarin treatment increased PVT median volume from 1.95 cm3 at week 2 to 3.78 cm3 at month 6 (P = 0.002). None of the 30 patients in the rivaroxaban group had clinically significant gastrointestinal bleeding, while 2 of the 30 patients (7%) in the warfarin group had gastrointestinal bleeding (P = 0.317).
CONCLUSION: Rivaroxaban followed by LMWH-Ca is an effective anticoagulant treatment strategy for PVT in cirrhosis.
This is a single site nonrandomized feasibility study of approximately 50 participants on treatment and/or surveillance for new or existing diagnoses of lung cancer who will be assigned to a single-arm involving monitoring of their patient-reported outcomes using a mobile medical application. The study procedures include monitoring of patient symptoms using automated weekly PRO surveys delivered by Moovcare® and assessment of outcomes including quality of life at baseline and at monthly intervals, as well as patient satisfaction at 6 months. The clinical care team will receive an alert if the PRO survey suggests increased or worsening symptoms. The care team will follow their usual protocols for the management of symptoms. The patient clinical information will also be abstracted from the medical record to assess clinical outcomes. The provider's satisfaction survey will be assessed via surveys.
A stable emulsification system comprising an oil bead composition, comprising: (1) an emulsified substrate; and (2) an oil bead composition. The emulsion substrate comprises an aqueous phase and an oil phase. The aqueous phase comprises an emulsifier, and the oil phase comprises oil. The emulsifier is an emulsifier comprising PEG and a polyglycerol group. The oil bead composition comprises: (i) an aqueous substrate; and (ii) oil beads dispersed in the aqueous substrate. The aqueous substrate comprises a thickener. The oil beads comprise one or more humectants comprising a saturated fatty alcohol of C  16 -C  24 . A preparation method for an emulsification system, and a formulation comprising the emulsification system are provided.
The somatosensory system is widely studied to understand its functioning mechanisms. Multiple tests, based on different devices and methods, have been performed not only on humans but also on animals andex-vivomodels. Depending on the nature of the sample under analysis and on the scientific aims of interest, several solutions for experimental stimulation and for investigations on sensation or pain have been adopted. In this review paper, an overview of the available devices and methods has been reported, also analyzing the representative values adopted during literature experiments. Among the various physical stimulations used to study the somatosensory system, we focused only on mechanical and thermal ones. Based on the analysis of their main features and on literature studies, we pointed out the most suitable solution for humans, rodents, andex-vivomodels and investigation aims (sensation and pain).
Chlorinated poly-(sulphonazides) of formula R(Cl)x(SO3N3)y where R is an aliphatic or cycloaliphatic radical containing at least 5 carbon atoms, e.g. polyethylene, polypropylene, polyisobutylene, and copolymers of ethylene and propylene, and X is an integer of at least one, and y an integer of at least two, are prepared by chlorinating and sulphochlorinating the hydrocarbon or mixtures thereof, and reacting the product with an alkali metal azide.  The compounds are suitable as cross-linking agents for polypropylene, particularly during foam preparation, and as flame-proofing agents.  Examples describe the use of the compounds prepared from hydrocarbon mixtures and mineral oil, as cross-linking agents for polyethylene and polypropylene, and the preparation of compounds using a copolymer of ethylene and propylene as the hydrocarbon to be treated.  An example describes the preparation of a stereo-regular polypropylene foam using azo bis-(formamide) as blowing agent, with a chlorinated poly-(sulphonazide) prepared from a commercial mixture of hydrocarbons (11-12C) as cross-linking agent.ALSO:The invention comprises chlorinated poly-(sulphonazides) of formula R(Cl)x(SO2N3)y where R is an aliphatic or cycloaliphatic radical containing at least 5 carbon atoms and x is an integer of at least 1, and y an integer of at least 2, prepared by chlorinating and sulphochlorinating an aliphatic or cycloaliphatic hydrocarbon or a mixture thereof to at least one chlorine and two sulphochloro groups per molecule of hydrocarbon, and reacting the product with an alkali metal azide to convert the sulphochloro groups to sulphonazide groups. Examples are dichlorodecane bis-(sulphonylazide, heptachlorooctadecane tris-(sulphonyl azide), chlorocyclohexane bis-(sulphonylazide) and other straight chain and alicyclic hydrocarbons to be treated are mentioned.  The chlorine and the sulphur dioxide are passed into liquid hydrocarbons (a solution or molten in the case of solid hydrocarbons) in the presence of ultra-violet light.  The compounds are suitable as cross-linking agents for polyolefines, particularly during the preparation of foams, and also as flame-proofing agents.